CompoAtlas

Lutéine-z 10 mg

Food supplement declared in France, declaration No 2019-10-304

Lutéine-z 10 mg is a food supplement declared in France. Status: withdrawn from the market (date not given in Compl'Alim). 3 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Jamieson Health Products UK Ltd.
Status
Withdrawn from the market (date not given in Compl'Alim)
Form
Capsule
Daily dose
1 gélule
Directions for use
Prendre une gélule par jour avec un repas.
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Taking away from meals, Children (under 12), Pregnant women, Taking anticoagulants, Taking antidepressants, Prolonged use

Declaration 336099, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Tagetes erecta L.FleurAutre extrait sec250 mg
Ginkgo biloba L.FeuilleAutre extrait sec40 mg
Vaccinium myrtillus L.FruitExtrait sec hydroalcoolique25 mg
Vitis vinifera L.PépinExtrait sec aqueux25 mg
Camellia sinensis (L.) KuntzeFeuilleAutre extrait sec3 mg

Additives

E464, E460, E341, E470b, E551

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Ne pas utiliser pendant la grossesse ou l'allaitement. Consultez votre médecin en cas de prise simultanée d'anticoagulants. L'emploi chez les personnes sous traitement antidépresseur est déconseillé. Consulter un médecin pour une utilisation au-delà de 3 mois. Ne doit pas être consommé par les adolescents et les enfants.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ginkgo biloba L.
    Read the warning, when it applies and the studies cited

    GINKGO - GINKGO BILOBA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Sources cited by Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindications

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Sources cited by Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Sources cited by Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Health Canada monograph dated 25 July 2025

  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line